Area of research
Hematology · Molecular Biology
Research interest
Research interests include Multiple Myeloma Research and Treatments, Amyloidosis: Diagnosis, Treatment, Outcomes, Immunotherapy and Immune Responses, and CAR-T cell therapy research.
Outcomes by Cardiac Stage in Patients With Newly Diagnosed AL Amyloidosis
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis
Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration
Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA
Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials
Reduction in Absolute Involved Free Light Chain and Difference between Involved and Uninvolved Free Light Chain Is Associated with Prolonged Major Organ Deterioration Progression-Free Survival in Patients with Newly Diagnosed AL Amyloidosis Receiving Bortezomib, Cyclophosphamide, and Dexamethasone with or without Daratumumab: Results from Andromeda
B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma
The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group
Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
Daratumumab (DARA) in combination with carfilzomib, lenalidomide, and dexamethasone (KRd) in patients (pts) with newly diagnosed multiple myeloma (MMY1001): An open-label, phase 1b study.
Daratumumab (DARA) in Combination with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) in Patients with Newly Diagnosed Multiple Myeloma (MMY1001): Updated Results from an Open-Label, Phase 1b Study
Patient and Kidney Allograft Survival in Recipients With End-Stage Renal Disease From Amyloidosis
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma
Second primary malignancies in multiple myeloma: an overview and IMWG consensus
Proteasome inhibitor associated thrombotic microangiopathy
NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma
Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study
Open-Label, Multicenter, Phase 1b Study of Daratumumab in Combination with Pomalidomide and Dexamethasone in Patients with at Least 2 Lines of Prior Therapy and Relapsed or Relapsed and Refractory Multiple Myeloma
Phase II study of daratumumab (DARA) monotherapy in patients with ≥ 3 lines of prior therapy or double refractory multiple myeloma (MM): 54767414MMY2002 (Sirius).
Clinical Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma